Biovica records SEK 2.3m in total net sales (22% above Q4 last year), and clinical sales increased by 120%. The outlook includes improved post-Q4 sales, the approaching support from Tempus AI later this calendar year, and a sound momentum in pharma-related sales. The company is executing a fully guaranteed rights issue of SEK 80m, sufficient to break even by Q3 2026/27 based on Biovica’s sales targets.
LÄS MER
